HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Claudia Rossig Selected Research

iratumumab

3/2021Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Claudia Rossig Research Topics

Disease

58Neoplasms (Cancer)
04/2022 - 01/2000
13Ewing Sarcoma (Sarcoma, Ewing)
06/2021 - 06/2013
10Neuroblastoma
01/2022 - 11/2008
9Sarcoma (Soft Tissue Sarcoma)
10/2021 - 01/2014
8Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2021 - 01/2019
6Leukemia
03/2021 - 01/2000
5Residual Neoplasm
11/2015 - 01/2006
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 05/2015
3Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 01/2000
3Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive)
01/2021 - 01/2019
3Myxoid Liposarcoma
01/2019 - 10/2017
2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2022 - 10/2017
2Osteosarcoma (Osteogenic Sarcoma)
10/2021 - 01/2021
2Lymphoma (Lymphomas)
03/2021 - 12/2019
2Mycoses (Diseases, Fungus)
03/2021 - 01/2018
2Infections
04/2019 - 01/2017
2Virus Diseases (Viral Diseases)
03/2015 - 07/2004
2Bone Marrow Failure Disorders
01/2015 - 07/2010
1Carcinogenesis
06/2022
1Toxic Optic Neuropathy
01/2022
1Glioma (Gliomas)
01/2022
1Hodgkin Disease (Hodgkin's Disease)
01/2022
1Central Nervous System Diseases (CNS Diseases)
01/2022
1Breast Neoplasms (Breast Cancer)
11/2021
1Bites and Stings (Sting)
03/2021

Drug/Important Bio-Agent (IBA)

24AntigensIBA
11/2021 - 12/2006
21Chimeric Antigen ReceptorsIBA
01/2022 - 11/2008
8Surface Antigens (Surface Antigen)IBA
10/2021 - 09/2007
5CytokinesIBA
01/2022 - 10/2014
5T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2022 - 03/2002
5Proteins (Proteins, Gene)FDA Link
01/2020 - 11/2015
5Biological ProductsIBA
01/2020 - 10/2011
4AntibodiesIBA
01/2022 - 01/2016
4blinatumomabIBA
10/2021 - 01/2020
4Inotuzumab OzogamicinIBA
03/2021 - 01/2019
4Neoplasm Antigens (Tumor Antigens)IBA
12/2019 - 01/2017
3Transcription Factors (Transcription Factor)IBA
06/2022 - 01/2019
3Monoclonal AntibodiesIBA
01/2022 - 10/2011
3Immunoconjugates (Immunoconjugate)IBA
01/2022 - 08/2013
3GD2 gangliosideIBA
10/2021 - 01/2018
3HLA-G Antigens (HLA G)IBA
06/2021 - 01/2017
3Immune Checkpoint InhibitorsIBA
03/2021 - 12/2019
3Pharmaceutical PreparationsIBA
04/2020 - 06/2013
3VaccinesIBA
07/2017 - 09/2007
2DNA (Deoxyribonucleic Acid)IBA
01/2022 - 11/2015
2HLA Antigens (Human Leukocyte Antigens)IBA
06/2021 - 04/2009
2Gemtuzumab (Mylotarg)FDA Link
03/2021 - 01/2019
2Etoposide (VP 16)FDA LinkGeneric
01/2021 - 10/2017
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2021 - 02/2013
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2020 - 08/2009
2Antiviral Agents (Antivirals)IBA
04/2019 - 03/2015
2LigandsIBA
01/2018 - 01/2017
2Cytarabine (Cytosar-U)FDA LinkGeneric
01/2018 - 05/2015
2Interleukin-2 (IL2)IBA
01/2016 - 05/2015
2Zoledronic Acid (Zometa)FDA Link
01/2016 - 06/2013
2EpitopesIBA
03/2012 - 04/2009
2Peptides (Polypeptides)IBA
03/2012 - 04/2009
2Viral AntigensIBA
03/2002 - 01/2000
1Phosphotransferases (Kinase)IBA
06/2022
1Protamines (Protamine Sulfate)FDA Link
01/2022
1BI 836858IBA
01/2022
1cobimetinibIBA
01/2022
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022
1SuspensionsIBA
01/2022
1TabletsIBA
01/2022
1DecitabineFDA Link
01/2022
1Small Interfering RNA (siRNA)IBA
01/2022
1Phenobarbital (Luminal)FDA Link
11/2021
1Hormones (Hormone)IBA
11/2021
1Immunotoxins (Immunotoxin)IBA
03/2021
1BW 250 183IBA
03/2021
1Abatacept (Orencia)FDA Link
03/2021
1Rituximab (Mabthera)FDA Link
03/2021
1pembrolizumabIBA
03/2021
1inolimomabIBA
03/2021
1combotoxIBA
03/2021
1daratumumabIBA
03/2021
1isatuximabIBA
03/2021
1obinutuzumabIBA
03/2021
1durvalumabIBA
03/2021
1Brentuximab VedotinIBA
03/2021
1immunotoxin HA22IBA
03/2021
1Alefacept (Amevive)FDA Link
03/2021
1avelumabIBA
03/2021
1NivolumabIBA
03/2021
1BasiliximabFDA Link
03/2021
1ofatumumabFDA Link
03/2021
1camrelizumabIBA
03/2021
1tremelimumabIBA
03/2021
1atezolizumabIBA
03/2021
1iratumumabIBA
03/2021
1axicabtagene ciloleucelIBA
03/2021

Therapy/Procedure

32Therapeutics
01/2022 - 01/2000
16Immunotherapy
04/2022 - 01/2006
8Drug Therapy (Chemotherapy)
01/2021 - 01/2006
6Hematopoietic Stem Cell Transplantation
10/2019 - 01/2015
3Stem Cell Transplantation
04/2019 - 07/2010
3Transplantation
04/2019 - 07/2010
2Combined Modality Therapy
02/2016 - 06/2013
1Molecular Targeted Therapy
06/2022